Abstract
The combination of investigation of rare Mendelian forms of hypertension, candidate gene studies, comparative mapping and genome-wide screening in both animal models and man has led to significant progress in determining new mechanisms of blood pressure control. In this review, the newly discovered blood pressure / cardiovascular genes, WNK kinases and angiotensin converting enzyme 2 and the development of a new anti-hypertensive agent PST2238 are discussed. Major genes causing essential hypertension have yet to be discovered, however, there are now over 20 published genome-wide screens for blood pressure controlling genes. Several regions demonstrate suggestive linkage to the trait and there is some overlap of regions between the different studies. It is hoped that new blood pressure genes will ultimately be discovered using this method. Pharmacogenetic studies in hypertension have only been initiated recently, some are described in this paper. Small studies upon single candidate genes, suggest that the contribution of genetics to the inter-individual variation in blood pressure response to anti-hypertensive therapy, is small, approximately 3-5%. Recently micro-arrays with multiple polymorphisms in multiple genes have been used. After accounting for the additive affects of multiple blood pressure loci, an individuals genetic profile appeared to explain up to 50% of the variation in blood pressure response to therapy. Knowledge of the genetic variants that cause hypertension and influence response to anti-hypertensive therapy will ultimately provide a greater understanding of the molecular mechanisms underlying blood pressure control.
Keywords: essential hypertension, blood pressure, single nucleotide polymorphisms, renin-angiotensin system, adducin
Current Pharmaceutical Design
Title: Genes and Hypertension
Volume: 9 Issue: 21
Author(s): E. A. Garcia, S. Newhouse, M. J. Caulfield and P. B. Munroe
Affiliation:
Keywords: essential hypertension, blood pressure, single nucleotide polymorphisms, renin-angiotensin system, adducin
Abstract: The combination of investigation of rare Mendelian forms of hypertension, candidate gene studies, comparative mapping and genome-wide screening in both animal models and man has led to significant progress in determining new mechanisms of blood pressure control. In this review, the newly discovered blood pressure / cardiovascular genes, WNK kinases and angiotensin converting enzyme 2 and the development of a new anti-hypertensive agent PST2238 are discussed. Major genes causing essential hypertension have yet to be discovered, however, there are now over 20 published genome-wide screens for blood pressure controlling genes. Several regions demonstrate suggestive linkage to the trait and there is some overlap of regions between the different studies. It is hoped that new blood pressure genes will ultimately be discovered using this method. Pharmacogenetic studies in hypertension have only been initiated recently, some are described in this paper. Small studies upon single candidate genes, suggest that the contribution of genetics to the inter-individual variation in blood pressure response to anti-hypertensive therapy, is small, approximately 3-5%. Recently micro-arrays with multiple polymorphisms in multiple genes have been used. After accounting for the additive affects of multiple blood pressure loci, an individuals genetic profile appeared to explain up to 50% of the variation in blood pressure response to therapy. Knowledge of the genetic variants that cause hypertension and influence response to anti-hypertensive therapy will ultimately provide a greater understanding of the molecular mechanisms underlying blood pressure control.
Export Options
About this article
Cite this article as:
Garcia A. E., Newhouse S., Caulfield J. M. and Munroe B. P., Genes and Hypertension, Current Pharmaceutical Design 2003; 9 (21) . https://dx.doi.org/10.2174/1381612033454513
DOI https://dx.doi.org/10.2174/1381612033454513 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Febuxostat: A Novel Non-Purine Selective Inhibitor of Xanthine Oxidase for the Treatment of Hyperuricemia in Gout
Recent Patents on Inflammation & Allergy Drug Discovery Response to <i>Letter to the Editor</i> by Briana and Malamitsi-Puchner: Effects of Pregnancy-induced Insulin Resistance on the Fetus and the Future Development of Metabolic Diseases in Adulthood
Current Vascular Pharmacology The U-shaped Relationship Between Serum Methylene Tetrahydrofolate Reductase and Large-artery Atherosclerotic Stroke
Current Neurovascular Research Trace and Minor Element Concentrations in Aqueous Extract of the Herbal Medicinal Plants Tamarindus indica and Hibiscus sabdiffora
Current Nutrition & Food Science Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition
Current Vascular Pharmacology Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]
Current Vascular Pharmacology Synthesis and Cholinesterase Inhibition Activity of New Pyrrolopyrimidine Derivatives
Letters in Drug Design & Discovery Managing Cardiovascular Risk Factors without Medications: What is the Evidence?
Cardiovascular & Hematological Agents in Medicinal Chemistry A New Gene Delivery System Based on Controlled Release Technology
Current Drug Delivery The Role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia
Current Pharmaceutical Biotechnology The Role of Nitric Oxide on Endothelial Function
Current Vascular Pharmacology Hypertension in Children with Cystic Kidney Diseases
Current Hypertension Reviews NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus
Current Diabetes Reviews Future of Cardiac Pacemaker – an Update of Biological Pacemaker Patents
Recent Patents on Biomedical Engineering (Discontinued) Non-Invasive Markers of Liver Fibrosis in HCV Mono-Infected and in HIV/HCV Co-Infected Subjects
Medicinal Chemistry Editorial
Current Medical Imaging Development of a Novel Nanocomposite Based on Reduced Graphene Oxide/Chitosan/Au/ZnO and Electrochemical Sensor for Determination of Losartan
Current Analytical Chemistry Usefulness of Home Blood Pressure in the Diagnosis and Control of Hypertension in Primary Care
Current Hypertension Reviews Colchicine in Coronary Artery Disease: An Old Acquaintance in New Attire?
Current Medicinal Chemistry